As impaired mitophagy and mitochondrial dysfunction are implicated in NAFLD, targeting PINK1/Parkin pathway to restore mitochondrial quality 58, the disrupted AMPK/PPARα signaling-resulted enhanced β-oxidation 59, dysregulated ER stress 58, PI3K/Akt signaling cascade and inflammatory responses 59 are reported as potential therapeutic strategies. The gene discussed is PRKN; the disease is metabolic dysfunction-associated steatotic liver disease.